Duration of Dual Antiretroviral Therapy in Virologically Suppressed People Living With HIV and Factors Associated With Switching to Tritherapy : a Real-life Cohort

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

580 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-01-01

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HIV infection requires lifelong continuous antiretroviral (ARV) treatment. The efficacy of current ARV treatments makes it possible to propose strategies for reducing the cumulative exposure to ARVs, side effects and costs. And so improve the quality of life of people living with HIV (PLHIV). However, in the real world, less regular adherence to treatment, more heavily pre-treated patients and resistance to treatment make these dual therapies prescribed beyond the strict framework of clinical trials. This can lead to undesirable side effects. From the perspective of personalized medicine, it seems to be important to determine which patients are receiving dual ARV therapy, and which patients remain on it for a long time. Identifying prognostic factors would enable us to adapt therapeutic management.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial

NCT04553081

HIV-1-infection

RECRUITING PHASE4

Reducing Antiretroviral Treatments

NCT04051970

HIV-1-infection

UNKNOWN PHASE3

Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)

NCT03447873

HIV Infections

COMPLETED PHASE4

Cohort of Patients Naive of Antiretroviral Treatment at Enrollment

NCT03137797

HIV Infection

COMPLETED

Patient-Reported Outcomes HIV BItherapy

NCT04788784

HIV/AIDS and Infections Patient Preference

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dual therapy

The evaluation will focus on the retention of patients living with hiv on dual antiretroviral therapy.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hiv patient
* viral load \< 50copies/ml
* patient treated with dual therapy
* patients with hospital follow-up between 2011 and 2023

Exclusion Criteria

* adults under legal protection
* underage

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier DRON

Tourcoing, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHT/URC/2023/13

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens

NCT00627055 COMPLETED PHASE4

Comparison of Inflammatory Markers and Incidence of Comorbidities in Patients on Antiretroviral Therapy With Second-generation Anti-integrase Drugs on Triple Versus Dual Therapy

NCT05699785 RECRUITING NA

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

NCT01252940 COMPLETED PHASE3

Strategic Timing of Antiretroviral Treatment

NCT00867048 COMPLETED PHASE4

Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults

NCT00820118 COMPLETED PHASE2

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

NCT01266902 COMPLETED PHASE3

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

NCT01772940 COMPLETED PHASE4

Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression

NCT02491242 COMPLETED

Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults

NCT00608569 COMPLETED NA

Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART)

NCT00122551 TERMINATED PHASE3

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

NCT06203132 RECRUITING PHASE3

Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR

NCT01286740 COMPLETED PHASE2

Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events

NCT01417949 COMPLETED PHASE4

Intermittent Versus Continuous Medication in the Treatment of HIV

NCT00001967 COMPLETED PHASE4

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795 COMPLETED PHASE3

ART First-line Treatment Durability in Russia

NCT04253119 COMPLETED

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

NCT01565850 COMPLETED PHASE2

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732 COMPLETED PHASE3

Dynamics of Drug Resistance-associated Mutations in HIV-1 DNA Reverse Transcriptase Clearance During Effective Antiretroviral Therapy

NCT04448158 COMPLETED

Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

NCT01006005 COMPLETED

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

NCT01928407 COMPLETED PHASE4

Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

NCT00120783 TERMINATED PHASE2

Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir

NCT06640192 RECRUITING PHASE2

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

NCT02656511 ACTIVE_NOT_RECRUITING PHASE4

REal-Life Cohort With DOlutegravir + LAmivudina

NCT04638686 COMPLETED